M. Hardy

A new model to evaluate the long-term cost effectiveness of orphan and highly specialised drugs following listing on the Australian Pharmaceutical Benefits Scheme: the Bosentan Patient Registry

J. Spinks, J. Wlodarczyk, A. Owen, 2008, Journal of medical economics.

RANDOMIZED TRIAL OF TACROLIMUS PLUS MYCOPHENOLATE MOFETIL OR AZATHIOPRINE VERSUS CYCLOSPORINE ORAL SOLUTION (MODIFIED) PLUS MYCOPHENOLATE MOFETIL AFTER CADAVERIC KIDNEY TRANSPLANTATION: RESULTS AT 2 YEARS1

M. Stegall, G. Danovitch, P. Halloran, 2001, Transplantation.

Medicinal Cannabis for the Treatment of Chronic Refractory Pain: An Investigation of the Adverse Event Profile and Health-Related Quality of Life Impact of an Oral Formulation

J. Barlow, L. Warne, M. Hardy, 2022, Medical Cannabis and Cannabinoids.

Understanding an emerging treatment population: Protocol for and baseline characteristics of a prospective cohort of people receiving treatment for pharmaceutical opioid dependence.

R. Bruno, S. Nielsen, B. Larance, 2018, Drug and alcohol review.

Understanding the health and service needs of diverse populations of pharmaceutical opioid users: Cohort studies of dependent users in treatment, and people who inject drugs

R. Bruno, S. Nielsen, B. Larance, 2015 .

Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation.

M. Stegall, G. Danovitch, P. Halloran, 2000, Transplantation.